Clinical Research Details

Back to List
Descriptive Information
A multicenter, double –blind, randomized, active controlled, parallel group, non-inferiority study comparing 75 mg Risedronate dosed on two consecutive days monthly with 5 mg daily Risedronate in the treatment of postmenopausal osteoporosis as assessed over 24 months. Aventis. 2005-2007.

Ghada El-Hajj Fuleihan
gf01@aub.edu.lb

IM.GE.HF.
Completed

Clinical Research - Clinical Trials (phase 0, 1,2 3 & 4)  

Phase 3  

No
Coordinators
Ali Hammoudi
ah80@aub.edu.lb
Extension: 7415
Conditions and Keywords
postmenopausal osteoporosis
Osteoporosis ,Risedronate,postmenopausal women,bone loss
Study Design
Treatment
Safety and/or Efficacy Study
Prospective
Double Blind
Parallel-Group
Randomized
Other
Eligibility and IRB
Female
Min: 50
Max:
Yes
No

 

 

 

 

 

Back to List